These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30126707)

  • 1. Pharmacovigilance: An Overview.
    Beninger P
    Clin Ther; 2018 Dec; 40(12):1991-2004. PubMed ID: 30126707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal Management in Pharmacovigilance: A Review of Activities and Case Studies.
    Beninger P
    Clin Ther; 2020 Jun; 42(6):1110-1129. PubMed ID: 32487428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance in Crisis: Drug Safety at a Crossroads.
    Price J
    Clin Ther; 2018 May; 40(5):790-797. PubMed ID: 29605513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.
    Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
    Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance strategy: opportunities for cross-national learning.
    Fermont I
    Isr J Health Policy Res; 2019 Jun; 8(1):54. PubMed ID: 31217025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance in oncology: evaluation of current practice and future perspectives.
    Baldo P; De Paoli P
    J Eval Clin Pract; 2014 Oct; 20(5):559-69. PubMed ID: 24909067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations.
    Peters T; Soanes N; Abbas M; Ahmad J; Delumeau JC; Herrero-Martinez E; Paramananda M; Piper J; Smail-Aoudia F; van der Spuij W; Veizovic T; Winstanley G;
    Drug Saf; 2021 Jan; 44(1):17-28. PubMed ID: 33289904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Safety Surveillance Plan for the Academic Medicine Sponsor Performing First-in-Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy.
    Adams C; Keller M; Michlitsch JG; Aguayo-Hiraldo P; Chen K; Hossain MZ; Davis A; Park JR; Verneris MR; Gardner RA
    Transplant Cell Ther; 2024 May; 30(5):475-487. PubMed ID: 38447751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role and Responsibilities of Various Stakeholders in Pharmacovigilance (PV).
    Phougat P; Beniwal M; Kapoor G; Aggarwal N; Kumari A; Sharma R; Chopra H; Sharma R; Kamal MA
    Curr Drug Saf; 2024 Feb; ():. PubMed ID: 38318830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities for Collaboration at the Interface of Pharmacovigilance and Manufacturing.
    Beninger P
    Clin Ther; 2017 Apr; 39(4):702-712. PubMed ID: 28366594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements.
    Maigetter K; Pollock AM; Kadam A; Ward K; Weiss MG
    Int J Health Policy Manag; 2015 Mar; 4(5):295-305. PubMed ID: 25905480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation.
    Mockute R; Desai S; Perera S; Assuncao B; Danysz K; Tetarenko N; Gaddam D; Abatemarco D; Widdowson M; Beauchamp S; Cicirello S; Mingle E
    Pharmaceut Med; 2019 Apr; 33(2):109-120. PubMed ID: 31933254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating Regulatory Drug Label Information to Facilitate Evaluation of Adverse Events in Pharmacovigilance.
    Hui TZ
    Curr Drug Saf; 2020; 15(2):124-130. PubMed ID: 32091345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance activities in ASEAN countries.
    Suwankesawong W; Dhippayom T; Tan-Koi WC; Kongkaew C
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1061-9. PubMed ID: 27174034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.